Vascepa is a prescription medication used to treat high levels of triglycerides in the blood. According to the sources provided, Vascepa is primarily marketed and sold in the United States. The drug is manufactured by Amarin Corporation, a biopharmaceutical company based in Dublin, Ireland, and has been approved by the US Food and Drug Administration (FDA) since 2012 [1].

There is no information provided in the sources about Vascepa being marketed or sold in any other country. However, Amarin Corporation has stated that they plan to expand Vascepa's market potential in the United States by increasing its salesforce and investing in marketing and promotional activities [2].

In summary, according to the sources provided, Vascepa is primarily marketed and sold in the United States, and there is no information about the drug being marketed or sold in any other country.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/VASCEPA
[2] https://investor.amarincorp.com/news-releases/news-release-details/amarin-announces-plans-maximize-blockbuster-potential-vascepar
[3] https://www.vascepa.com/